Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

Exclusion Criteria

• •Subjects with any other acne-like dermatological conditions such as severe, recalcitrant nodulocystic acne, acne conglobata, acne fulminans, acne secondary to medications or other medical conditions, perioral dermatitis, clinically significant rosacea, or gram-negative folliculitis;
• •Any subject with skin disorders of an acute or chronic nature including psoriasis, eczema, tinea versicolor, etc.
• •Subjects who reside in a dwelling that relies on well water for a primary drinking source
• •Subjects with facial hair (beards, mustaches, etc.), tattoos or other facial markings that would interfere with assessments and study drug application
• •Transgender subjects receiving hormone supplement (male to female or female to male)
• •Subjects with a previous history of methemoglobinemia or taking medications known to be associated with methemoglobinemia
• •Subjects with a known history of HIV, hepatitis, or other blood-borne pathogens
• •Females who are pregnant, planning a pregnancy or breastfeeding
• •Subjects previously treated with NVN1000 Gel / SB204